Alexandra Ya. Gudkova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Alexandra Ya. Gudkova has a total of 135 co-authors. Here are the top co-authors by number of shared publications:
- Anna A. Kostareva
Almazov National Medical Research Centre
17 shared publications - A. A. Poliakova
Pavlov University
10 shared publications - Alexander Krutikov
Pavlov University; Almazov National Medical Research Centre
10 shared publications - T. G. Bezhanishvili
Pavlov University
8 shared publications - V. G. Davydova
Saint Petersburg City Hospital No 40
8 shared publications - A. A. Streltsova
Almazov National Medical Research Centre
7 shared publications
Latest Publications
- Open Access
- 9 October 2026
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in The Scientific Notes of the Pavlov University
- Vol. 33 (2) , 40-48
Associations of the single nucleotide polymorphism rs2228145 of the IL6R gene with features of the clinical course of hypertrophic cardiomyopathy
Introduction. The study of modifiable cardiometabolic risk factors (CMRFs) influencing the clinical phenotype of hypertrophic cardiomyopathy (HCM) is currently relevant. It is known that modifier genes can affect the course and progression of symptoms in HCM. At the same time, the analysis of associations between single nucleotide variants of the interleukin-6 receptor gene (IL6R) and the specifics of the clinical course of HCM remains a poorly studied area. The objective was to investigate the associations of the SNP rs2228145 of the IL6R gene with HCM, the presence of arterial hypertension (AH) in patients with HCM, age at diagnosis and serum concentrations of C-reactive protein (CRP) and interleukin-6 (IL-6). Methods and materials. The analysis of the SNP rs2228145 of the IL6R gene was conducted in 218 adult patients with HCM aged >18 years (median 53 [35.3; 64] years) and in 200 individuals from a comparison group (general population). Results. It was found that the CC genotype was more common in the group of patients with HCM than in the general population (p=0.005). Carriage of the CC genotype of rs2228145 was associated with a 3.64-fold increased risk of HCM (OR=3.64; 95 % CI: 1.44–9.15; p=0.005). The CC genotype of rs2228145 of the IL6R gene was more prevalent among HCM patients with concomitant AH (n=134) compared to HCM patients without AH (14.9 % vs. 2.4 %, p=0.003) and was associated with a 7.29-fold increased risk of AH in HCM patients (OR=7.29; 95 % CI: 1.62–32.85; p=0.003) relative to the AA genotype. The C allele predominated in the HCM+AH group compared to the HCM without AH group (35.4 % vs. 25.6 %, p=0.03) and was associated with a 1.6-fold increased risk of AH in HCM patients (OR=1.6; 95 % CI: 1.04–2.45; p=0.03). Among HCM patients with concomitant AH aged ≥45 years (n=119), the age at diagnosis in CC genotype carriers was lower than in carriers of the AA and AC genotypes (59 [54.5; 62] years vs. 63 [57.3; 69.8] years, p=0.03). Serum CRP and IL-6 concentrations were higher in HCM patients aged ≥45 years with overweight or obesity than in HCM patients of the same age group with normal body weight: CRP – 2.9 [1.28; 4.23] mg/L vs. 1.4 [0.3; 2.42] mg/L (p=0.04); IL-6 – 1.42 [0.89; 3.37] pg/mL vs. 0.19 [0.11; 0.74] pg/mL (p=0.004), respectively. Conclusion. Carriage of the CC genotype of the rs2228145 variant of the IL6R gene increases the risk of HCM by 3.64-fold. Carriage of the CC genotype of rs2228145 is associated with a 7.29-fold increased risk of AH in HCM patients, while carriage of the C allele is associated with a 1.6-fold increased risk of AH in these patients. In HCM patients with concomitant AH aged over 45 years, carriage of the CC genotype was associated with a 4-year earlier diagnosis compared to carriers of the AA and AC genotypes. In HCM patients aged ≥45 years with overweight or obesity, serum CRP and IL-6 concentrations are higher than in normal-weight individuals of the same age.
- 9 October 2026
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in The Scientific Notes of the Pavlov University
- Vol. 33 (2) , 40-48
Open AccessAssociations of the single nucleotide polymorphism rs2228145 of the IL6R gene with features of the clinical course of hypertrophic cardiomyopathy
Introduction. The study of modifiable cardiometabolic risk factors (CMRFs) influencing the clinical phenotype of hypertrophic cardiomyopathy (HCM) is currently relevant. It is known that modifier genes can affect the course and progression of symptoms in HCM. At the same time, the analysis of associations between single nucleotide variants of the interleukin-6 receptor gene (IL6R) and the specifics of the clinical course of HCM remains a poorly studied area. The objective was to investigate the associations of the SNP rs2228145 of the IL6R gene with HCM, the presence of arterial hypertension (AH) in patients with HCM, age at diagnosis and serum concentrations of C-reactive protein (CRP) and interleukin-6 (IL-6). Methods and materials. The analysis of the SNP rs2228145 of the IL6R gene was conducted in 218 adult patients with HCM aged >18 years (median 53 [35.3; 64] years) and in 200 individuals from a comparison group (general population). Results. It was found that the CC genotype was more common in the group of patients with HCM than in the general population (p=0.005). Carriage of the CC genotype of rs2228145 was associated with a 3.64-fold increased risk of HCM (OR=3.64; 95 % CI: 1.44–9.15; p=0.005). The CC genotype of rs2228145 of the IL6R gene was more prevalent among HCM patients with concomitant AH (n=134) compared to HCM patients without AH (14.9 % vs. 2.4 %, p=0.003) and was associated with a 7.29-fold increased risk of AH in HCM patients (OR=7.29; 95 % CI: 1.62–32.85; p=0.003) relative to the AA genotype. The C allele predominated in the HCM+AH group compared to the HCM without AH group (35.4 % vs. 25.6 %, p=0.03) and was associated with a 1.6-fold increased risk of AH in HCM patients (OR=1.6; 95 % CI: 1.04–2.45; p=0.03). Among HCM patients with concomitant AH aged ≥45 years (n=119), the age at diagnosis in CC genotype carriers was lower than in carriers of the AA and AC genotypes (59 [54.5; 62] years vs. 63 [57.3; 69.8] years, p=0.03). Serum CRP and IL-6 concentrations were higher in HCM patients aged ≥45 years with overweight or obesity than in HCM patients of the same age group with normal body weight: CRP – 2.9 [1.28; 4.23] mg/L vs. 1.4 [0.3; 2.42] mg/L (p=0.04); IL-6 – 1.42 [0.89; 3.37] pg/mL vs. 0.19 [0.11; 0.74] pg/mL (p=0.004), respectively. Conclusion. Carriage of the CC genotype of the rs2228145 variant of the IL6R gene increases the risk of HCM by 3.64-fold. Carriage of the CC genotype of rs2228145 is associated with a 7.29-fold increased risk of AH in HCM patients, while carriage of the C allele is associated with a 1.6-fold increased risk of AH in these patients. In HCM patients with concomitant AH aged over 45 years, carriage of the CC genotype was associated with a 4-year earlier diagnosis compared to carriers of the AA and AC genotypes. In HCM patients aged ≥45 years with overweight or obesity, serum CRP and IL-6 concentrations are higher than in normal-weight individuals of the same age.
- Open Access
- 17 December 2025
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 12 (12) , 499
Genetic Spectrum, Clinical Characteristics, and Molecular Pathogenesis of Hypertrophic Cardiomyopathy Requiring Heart Transplantation
Hypertrophic cardiomyopathy (HCM) progressing to end-stage heart failure and heart transplantation (HT) is a rare clinical scenario with an insufficiently explored genetic background. In this single-center retrospective cohort study, we aimed to characterize the genetic spectrum, variants of HCM adverse remodeling, and aspects of molecular pathogenesis of this subgroup. The study included 14 patients (9 females), among whom 10 developed a dilated/hypokinetic phenotype and 4 a restrictive phenotype. In 13 patients (93%), at least one pathogenic or likely pathogenic genetic variant was identified. Dilated remodeling/hypokinesis was associated with loss-of-function variants in LAMP2 (3) in females, ALPK3homo (1), MYH7 (1), MYBPC3 (1), a heterozygous missense variant in TRIM63 (1), FLNCtv (1), TTNtv (2). For the latter two, electrophoretic analysis of titin isoform composition and protein content in myocardial fragments from explanted hearts confirmed the functional significance of TTN gene variants. The restrictive phenotype in the adult group was associated with carriage of multiple pathogenic sarcomere gene variants: MYL3homo (1), MYBPC3+TPM1 (1), an MYH7 converter domain variant (1), and, in one child, with a TNNT2 variant. This findings support HCM progressing to HT is characterized by a higher frequency of variants in non-sarcomeric genes and Danon disease compared to the general HCM cohort.
- 17 December 2025
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 12 (12) , 499
Open AccessGenetic Spectrum, Clinical Characteristics, and Molecular Pathogenesis of Hypertrophic Cardiomyopathy Requiring Heart Transplantation
Hypertrophic cardiomyopathy (HCM) progressing to end-stage heart failure and heart transplantation (HT) is a rare clinical scenario with an insufficiently explored genetic background. In this single-center retrospective cohort study, we aimed to characterize the genetic spectrum, variants of HCM adverse remodeling, and aspects of molecular pathogenesis of this subgroup. The study included 14 patients (9 females), among whom 10 developed a dilated/hypokinetic phenotype and 4 a restrictive phenotype. In 13 patients (93%), at least one pathogenic or likely pathogenic genetic variant was identified. Dilated remodeling/hypokinesis was associated with loss-of-function variants in LAMP2 (3) in females, ALPK3homo (1), MYH7 (1), MYBPC3 (1), a heterozygous missense variant in TRIM63 (1), FLNCtv (1), TTNtv (2). For the latter two, electrophoretic analysis of titin isoform composition and protein content in myocardial fragments from explanted hearts confirmed the functional significance of TTN gene variants. The restrictive phenotype in the adult group was associated with carriage of multiple pathogenic sarcomere gene variants: MYL3homo (1), MYBPC3+TPM1 (1), an MYH7 converter domain variant (1), and, in one child, with a TNNT2 variant. This findings support HCM progressing to HT is characterized by a higher frequency of variants in non-sarcomeric genes and Danon disease compared to the general HCM cohort.
- Open Access
- 2 October 2025
- Published by MDPI AG in Preprints.org
Genetic Spectrum, Clinical Characteristics, and Molecular Pathogenesis of Hypertrophic Cardiomyopathy Requiring Heart Transplantation
Hypertrophic cardiomyopathy (HCM) progressing to end-stage heart failure and heart transplantation (HT) is a rare clinical scenario with insufficiently explored genetic background. In this single-center retrospective cohort study we aimed to characterize the genetic spectrum, variants of HCM adverse remodeling, and aspects of molecular pathogenesis of this subgroup. The study included 14 patients (9 females), among whom 10 developed a dilated/hypokinetic phenotype and 4 a restrictive phenotype. In 13 pa-tients (93%), at least one pathogenic or likely pathogenic genetic variant was identified. Dilated remodeling/hypokinesis was associated with loss-of-function variants in LAMP2 (3) in females, ALPK3homo (1), MYH7 (1), MYBPC3 (1), heterozygous missense variant in TRIM63 (1), FLNCtv (1), TTNtv (2). For the latter two electrophoretic analysis of titin isoform composition and protein content in myocardial fragments from ex-planted hearts confirmed the functional significance of TTN gene variants. The restric-tive phenotype in the adult group was associated with carriage of multiple pathogenic sarcomere gene variants: MYL3homo (1), MYBPC3+TPM1 (1), a MYH7 converter domain variant (1), and in 1 child, with a TNNT2 variant. This fundings supports HCM pro-gressing to HT is characterized by a higher frequency of variants in non-sarcomeric genes and Danon disease compared to the general HCM cohort.
- 2 October 2025
- Published by MDPI AG in Preprints.org
Open AccessGenetic Spectrum, Clinical Characteristics, and Molecular Pathogenesis of Hypertrophic Cardiomyopathy Requiring Heart Transplantation
Hypertrophic cardiomyopathy (HCM) progressing to end-stage heart failure and heart transplantation (HT) is a rare clinical scenario with insufficiently explored genetic background. In this single-center retrospective cohort study we aimed to characterize the genetic spectrum, variants of HCM adverse remodeling, and aspects of molecular pathogenesis of this subgroup. The study included 14 patients (9 females), among whom 10 developed a dilated/hypokinetic phenotype and 4 a restrictive phenotype. In 13 pa-tients (93%), at least one pathogenic or likely pathogenic genetic variant was identified. Dilated remodeling/hypokinesis was associated with loss-of-function variants in LAMP2 (3) in females, ALPK3homo (1), MYH7 (1), MYBPC3 (1), heterozygous missense variant in TRIM63 (1), FLNCtv (1), TTNtv (2). For the latter two electrophoretic analysis of titin isoform composition and protein content in myocardial fragments from ex-planted hearts confirmed the functional significance of TTN gene variants. The restric-tive phenotype in the adult group was associated with carriage of multiple pathogenic sarcomere gene variants: MYL3homo (1), MYBPC3+TPM1 (1), a MYH7 converter domain variant (1), and in 1 child, with a TNNT2 variant. This fundings supports HCM pro-gressing to HT is characterized by a higher frequency of variants in non-sarcomeric genes and Danon disease compared to the general HCM cohort.
- Open Access
- 7 September 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (11) , 5994
Clinical, morphological and genetic characteristics of young patients with hypertrophic cardiomyopathy with indications for implantable cardioverter-defibrillator
Aim. To study the clinical, morphological and genetic characteristics of young patients with hypertrophic cardiomyopathy (HCM) with indications for primary and secondary prevention of sudden cardiac death (SCD).Material and methods. The study included 44 young patients with HCM who were examined in accordance with national clinical guidelines for HCM (2020). The AHA HCM SCD Calculator was used to calculate the risk of SCD. The genetic study was performed using a target panel of 108 genes associated with cardiomyopathies.Results. In the study cohort, young patients in 72,7% of cases (n=32) had from 1 to 3 cardiometabolic risk factors (on average 1,53±0,8).The age of 18 patients with indications for implantable cardioverter-defibrillator (ICD) ranged from 18 to 44 years (28,8±2,2). The age at diagnosis was 18,5±7,4 years, while the asymptomatic period lasted 6,4±0,9 years. The estimated risk of SCD ranged from 3,11 to 20,71% (6,15 [4,67; 7,32]). In 83,3% of cases (n=15), familial HCM was diagnosed, while 50% (n=9) had a positive family history of SCD. In the subgroup of patients with indications for ICD, genetic variants with pathogenic significance (class IV and V) encoding the production of sarcomere proteins were detected in 6 of 9 probands (66,7%).In patients with indications for ICD (n=18), compared to patients without it (n=26), the diagnosis of HCM was more often established in childhood and adolescence (61,1% vs 23%, p=0,01). In patients with indications for ICD, the reverse curvature hypertrophy of the interventricular septum was significantly more often diagnosed (72,2% vs 38,5%, p=0,028). Among patients with indications for ICD, the proportion of people with low physical activity was 50% (n=9), of which 55,6% (n=5) were diagnosed with overweight/class 1 obesity.Conclusion. Childhood and adolescence at the time of diagnosis of HCM and reverse curvature hypertrophy of the interventricular septum are significantly more common in young patients with indications for ICD.
- 7 September 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (11) , 5994
Open AccessClinical, morphological and genetic characteristics of young patients with hypertrophic cardiomyopathy with indications for implantable cardioverter-defibrillator
Aim. To study the clinical, morphological and genetic characteristics of young patients with hypertrophic cardiomyopathy (HCM) with indications for primary and secondary prevention of sudden cardiac death (SCD).Material and methods. The study included 44 young patients with HCM who were examined in accordance with national clinical guidelines for HCM (2020). The AHA HCM SCD Calculator was used to calculate the risk of SCD. The genetic study was performed using a target panel of 108 genes associated with cardiomyopathies.Results. In the study cohort, young patients in 72,7% of cases (n=32) had from 1 to 3 cardiometabolic risk factors (on average 1,53±0,8).The age of 18 patients with indications for implantable cardioverter-defibrillator (ICD) ranged from 18 to 44 years (28,8±2,2). The age at diagnosis was 18,5±7,4 years, while the asymptomatic period lasted 6,4±0,9 years. The estimated risk of SCD ranged from 3,11 to 20,71% (6,15 [4,67; 7,32]). In 83,3% of cases (n=15), familial HCM was diagnosed, while 50% (n=9) had a positive family history of SCD. In the subgroup of patients with indications for ICD, genetic variants with pathogenic significance (class IV and V) encoding the production of sarcomere proteins were detected in 6 of 9 probands (66,7%).In patients with indications for ICD (n=18), compared to patients without it (n=26), the diagnosis of HCM was more often established in childhood and adolescence (61,1% vs 23%, p=0,01). In patients with indications for ICD, the reverse curvature hypertrophy of the interventricular septum was significantly more often diagnosed (72,2% vs 38,5%, p=0,028). Among patients with indications for ICD, the proportion of people with low physical activity was 50% (n=9), of which 55,6% (n=5) were diagnosed with overweight/class 1 obesity.Conclusion. Childhood and adolescence at the time of diagnosis of HCM and reverse curvature hypertrophy of the interventricular septum are significantly more common in young patients with indications for ICD.
- Open Access
- 19 August 2024
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in New St. Petersburg Medical Records
- No. 1,p. 42-56
Diagnosis of wild-type transthyretin amyloid cardiomyopathy by primary care physicians in Saint Petersburg. Literature review and clinical case
Cardiac age-related transthyretin amyloidosis is an underdiagnosed reason of heart failure with preserved ejection fraction, the most frequent form of heart failure. We present a clinical case of detection of transthyretin amyloidosis of the heart at stage I-II of the disease based on biomarkers, which made it possible to send the patient to a third-level hospital and achieve the maximum possible compensation for the disease. Based on this case report, we review modern algorithms allowing to suspect and make the diagnosis, from performing routine tests like ECG and echocardiography to more sophisticated instruments like 2D strain-echocardiography, radiology and endomyocardial biopsy. Also staging systems using biomarkers for cardiac transthyretin amyloidosis are discussed. We consider possible paths to early diagnosis of this disease and nuances of medical therapy.
- 19 August 2024
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in New St. Petersburg Medical Records
- No. 1,p. 42-56
Open AccessDiagnosis of wild-type transthyretin amyloid cardiomyopathy by primary care physicians in Saint Petersburg. Literature review and clinical case
Cardiac age-related transthyretin amyloidosis is an underdiagnosed reason of heart failure with preserved ejection fraction, the most frequent form of heart failure. We present a clinical case of detection of transthyretin amyloidosis of the heart at stage I-II of the disease based on biomarkers, which made it possible to send the patient to a third-level hospital and achieve the maximum possible compensation for the disease. Based on this case report, we review modern algorithms allowing to suspect and make the diagnosis, from performing routine tests like ECG and echocardiography to more sophisticated instruments like 2D strain-echocardiography, radiology and endomyocardial biopsy. Also staging systems using biomarkers for cardiac transthyretin amyloidosis are discussed. We consider possible paths to early diagnosis of this disease and nuances of medical therapy.
- Open Access
- 20 May 2024
- Published by ECO-Vector LLC in Medical academic journal
- Vol. 24 (1) , 67-82
Transthyretin amyloidosis. Fundamentals of pathogenesis, diagnosis, treatment, prognosis
Among the 42 human amyloidoses described to date the so-called systemic transthyretin amyloidosis, which comprises hereditary forms (more than 140 variants in accordance with the number of identified mutations in the transthyretin gene) and a sporadic form without structural changes in the gene and the protein, is of particular interest. This review summarizes modern understandings of pathogenesis of transthyretin amyloidosis. The symptoms of different forms of transthyretin amyloidosis, issues of early diagnosis, differential diagnosis (including within the group of amyloidoses), advanced therapy and prognosis are considered. Special attention is given to the non-mutant form of transthyretin amyloidosis, the so-called senile amyloidosis, which significantly complicates the course of underlying pathologies in the age group older than 70 years and is still poorly diagnosed. A quite high occurrence of non-mutant form of transthyretin amyloidosis makes it to be considered as a socially significant disease.
- 20 May 2024
- Published by ECO-Vector LLC in Medical academic journal
- Vol. 24 (1) , 67-82
Open AccessTransthyretin amyloidosis. Fundamentals of pathogenesis, diagnosis, treatment, prognosis
Among the 42 human amyloidoses described to date the so-called systemic transthyretin amyloidosis, which comprises hereditary forms (more than 140 variants in accordance with the number of identified mutations in the transthyretin gene) and a sporadic form without structural changes in the gene and the protein, is of particular interest. This review summarizes modern understandings of pathogenesis of transthyretin amyloidosis. The symptoms of different forms of transthyretin amyloidosis, issues of early diagnosis, differential diagnosis (including within the group of amyloidoses), advanced therapy and prognosis are considered. Special attention is given to the non-mutant form of transthyretin amyloidosis, the so-called senile amyloidosis, which significantly complicates the course of underlying pathologies in the age group older than 70 years and is still poorly diagnosed. A quite high occurrence of non-mutant form of transthyretin amyloidosis makes it to be considered as a socially significant disease.
- Open Access
- 7 March 2023
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in The Scientific Notes of the Pavlov University
- Vol. 30 (1) , 50-61
Clinical features of hypertrophic cardiomyopathy depending on the hereditary factor
The objective was to study the clinical features of symptomatic hypertrophic cardiomyopathy (HCM) depending on the form (familial / non-familial), the age of onset and the presence of arterial hypertension (AH).Methods and materials. During 6 years, we examined 250 HCM patients, 100 patients with symptomatic HCM aged from 18 to 86 years were included in the study. Results. Patients with the clinical manifestations onset at a young age more often had a familial form of the disease, an autosomal dominant type of inheritance, an asymmetric HCM with reverse curve interventricular septal morphology. On the contrary, patients with the clinical manifestations onset at the age of ≥45 years had non-familial form of the disease and asymmetric HCM with basal interventricular septal hypertrophy. The young HCM patients with associated AH more often were obese, had CHF of III–IV functional class (NYHA), larger anteroposterior left atrial diameter than patients without AH and more often needed interventricular septal reduction. HCM patients and associated AH with the disease onset at the age of ≥45 years significantly more often had angina syndrome. Absolute indications for interventricular septal reduction in HCM patients with the disease onset ≥45 years of age were determined only for HCM patients and associated AH. At the same time, 50 % of HCM+AH patients both at a young age and in the older group, had obesity. Conclusions. The interventricular septal morphology differs significantly depending on the age of clinical manifestations onset. Co-existing AH and obesity are predictors of the progressive HCM course and an increase in the proportion of patients with absolute indications for interventricular septal reductions regardless of the age of clinical manifestations onset.
- 7 March 2023
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in The Scientific Notes of the Pavlov University
- Vol. 30 (1) , 50-61
Open AccessClinical features of hypertrophic cardiomyopathy depending on the hereditary factor
The objective was to study the clinical features of symptomatic hypertrophic cardiomyopathy (HCM) depending on the form (familial / non-familial), the age of onset and the presence of arterial hypertension (AH).Methods and materials. During 6 years, we examined 250 HCM patients, 100 patients with symptomatic HCM aged from 18 to 86 years were included in the study. Results. Patients with the clinical manifestations onset at a young age more often had a familial form of the disease, an autosomal dominant type of inheritance, an asymmetric HCM with reverse curve interventricular septal morphology. On the contrary, patients with the clinical manifestations onset at the age of ≥45 years had non-familial form of the disease and asymmetric HCM with basal interventricular septal hypertrophy. The young HCM patients with associated AH more often were obese, had CHF of III–IV functional class (NYHA), larger anteroposterior left atrial diameter than patients without AH and more often needed interventricular septal reduction. HCM patients and associated AH with the disease onset at the age of ≥45 years significantly more often had angina syndrome. Absolute indications for interventricular septal reduction in HCM patients with the disease onset ≥45 years of age were determined only for HCM patients and associated AH. At the same time, 50 % of HCM+AH patients both at a young age and in the older group, had obesity. Conclusions. The interventricular septal morphology differs significantly depending on the age of clinical manifestations onset. Co-existing AH and obesity are predictors of the progressive HCM course and an increase in the proportion of patients with absolute indications for interventricular septal reductions regardless of the age of clinical manifestations onset.
- Open Access
- 26 December 2022
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 94 (11) , 1225-1233
Informativeness estimation for the main clinical and laboratory parameters in patients with severe COVID-19
Aim. To conduct a retrospective assessment of the clinical and laboratory data of patients with severe forms of COVID-19 hospitalized in the intensive care and intensive care unit, in order to assess the contribution of various indicators to the likelihood of death. Materials and methods. A retrospective assessment of data on 224 patients with severe COVID-19 admitted to the intensive care unit was carried out. The analysis included the data of biochemical, clinical blood tests, coagulograms, indicators of the inflammatory response. When transferring to the intensive care units (ICU), the indicators of the formalized SOFA and APACHE scales were recorded. Anthropometric and demographic data were downloaded separately. Results. Analysis of obtained data, showed that only one demographic feature (age) and a fairly large number of laboratory parameters can serve as possible markers of an unfavorable prognosis. We identified 12 laboratory features the best in terms of prediction: procalcitonin, lymphocytes (absolute value), sodium (ABS), creatinine, lactate (ABS), D-dimer, oxygenation index, direct bilirubin, urea, hemoglobin, C-reactive protein, age, LDH. The combination of these features allows to provide the quality of the forecast at the level of AUC=0.85, while the known scales provided less efficiency (APACHE: AUC=0.78, SOFA: AUC=0.74). Conclusion. Forecasting the outcome of the course of COVID-19 in patients in ICU is relevant not only from the position of adequate distribution of treatment measures, but also from the point of view of understanding the pathogenetic mechanisms of the development of the disease.
- 26 December 2022
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 94 (11) , 1225-1233
Open AccessInformativeness estimation for the main clinical and laboratory parameters in patients with severe COVID-19
Aim. To conduct a retrospective assessment of the clinical and laboratory data of patients with severe forms of COVID-19 hospitalized in the intensive care and intensive care unit, in order to assess the contribution of various indicators to the likelihood of death. Materials and methods. A retrospective assessment of data on 224 patients with severe COVID-19 admitted to the intensive care unit was carried out. The analysis included the data of biochemical, clinical blood tests, coagulograms, indicators of the inflammatory response. When transferring to the intensive care units (ICU), the indicators of the formalized SOFA and APACHE scales were recorded. Anthropometric and demographic data were downloaded separately. Results. Analysis of obtained data, showed that only one demographic feature (age) and a fairly large number of laboratory parameters can serve as possible markers of an unfavorable prognosis. We identified 12 laboratory features the best in terms of prediction: procalcitonin, lymphocytes (absolute value), sodium (ABS), creatinine, lactate (ABS), D-dimer, oxygenation index, direct bilirubin, urea, hemoglobin, C-reactive protein, age, LDH. The combination of these features allows to provide the quality of the forecast at the level of AUC=0.85, while the known scales provided less efficiency (APACHE: AUC=0.78, SOFA: AUC=0.74). Conclusion. Forecasting the outcome of the course of COVID-19 in patients in ICU is relevant not only from the position of adequate distribution of treatment measures, but also from the point of view of understanding the pathogenetic mechanisms of the development of the disease.